Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 89891-69-0 | MDL No. : | MFCD09261031 |
Formula : | C8H4BrNO | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | ADHKMYHLJHBOKB-UHFFFAOYSA-N |
M.W : | 210.03 | Pubchem ID : | 20510518 |
Synonyms : |
|
Num. heavy atoms : | 11 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 44.24 |
TPSA : | 40.86 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.89 cm/s |
Log Po/w (iLOGP) : | 1.57 |
Log Po/w (XLOGP3) : | 2.38 |
Log Po/w (WLOGP) : | 2.13 |
Log Po/w (MLOGP) : | 1.51 |
Log Po/w (SILICOS-IT) : | 2.63 |
Consensus Log Po/w : | 2.04 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.98 |
Solubility : | 0.22 mg/ml ; 0.00105 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.88 |
Solubility : | 0.278 mg/ml ; 0.00132 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.29 |
Solubility : | 0.107 mg/ml ; 0.000512 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.74 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
59.3% | With dimethyl sulfoxide In water at 120℃; for 6 h; | A solution of the product of Part 3A (8.80 g, 24.9 mmol) was dissolved in wet DMSO (83 mL) at ambient temperature then warmed to 120 °C and maintained 6 h. After cooling to ambient temperature, the resulting solution was diluted with H2O with transfer to a separatory funnel then washed EtOAc. The EtOAc solution was separated, washed with H2O and saturated aqueous NaCl then dried over Na2SO4, filtered and concentrated in vacuo to a yellow solid. Subsequent purification by chromatography on silica using 20: 1 hexanes/EtOAc afforded the title compound as a white solid (3.10 g, 14.8 mmol; 59.3percent). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
99% | With sodium tetrahydroborate In methanol at 0 - 25℃; | A solution of 3-bromo-4-formylbenzonitrile (1.0 g, 4.8 mmol) in CH3OH (30 niL) was cooled to 00C. NaBH4 (180 mg, 4.8 mmol) was added portionwise. The mixture was allowed to warm to room temperature and stirred at room temperature for 1 h. The mixture was qunched with IN HCl and concentrated under vacuum. The residue was extracted with ethyl acetate (25 mL*3). The combined organic layers were washed with brine (20 mL), dried (Na2SO4) and concentrated under vacuum to give a white solid of the desired compound (1.Og, 99percent). NMR (300 MHz, CDCl3): δ 7.82 (s, IH), 7.49-7.71 (m, 2H), 4.75 (s, 2H). LC-MS: 212 (M + I)+. |
99% | at 0 - 20℃; | A solution of 3-bromo-4-formylbenzonitrile A (1.0 g, 4.8 mmol) in CH3OH(30 niL) was cooled to 00C. NaBH4 (180 mg, 4.8 mmol) was added portionwise. The mixture was allowed to warm to room temperature and stirr at room temperature for 1 h. The mixture was qunched with IN HCl and concentrated under vacuum. The residue was extracted with ethyl acetate (25 mL*3). The combined organic layers were washed with brine (20 mL), dried (Na2SO4) and concentrated under vacuum to give a white solid of the desired compound B (1.Og, 990Zo)-1H NMR (300 MHz, CDCl3): δ 7.82 (s, IH), 7.49-7.71 (m, 2H), 4.75 (s, 2H). LC-MS: 212 (M + I)+. |
60.7% | at 0℃; for 0.666667 h; | A solution of the product of Part 3B (3.10 g, 14.7 mmol) was dissolved MeOH (74 mL) at ambient temperature then cooled to 0 °C using an ice bath. NaBH4 (0.279 g, 7.38 mmol) was then added in one portion and the resulting solution maintained 40 min at 0 °C. Dilute aqueous HCl was added to consume excess NaBH4 then all volatiles removed in vacuo. The residue was redissolved in EtOAc with transfer to a separatory funnel, successively washed with 5percent aqueous citric acid and H2O, then dried over Na2SO4, filtered and concentrated in vacuo. Purification by chromatography on silica using a step gradient from 9: 1 hexanes/EtOAc to 1 : 1 hexanes/EtOAc afforded the title compound as a white solid (1.90 g, 8.96 mmol; 60.7percent). |